Jakarta - PT Itama Ranoraya Tbk (IRRA) as of the first quarter of 2022 posted revenue of Rp269.85 billion, an increase of 18% compared to the same period the previous year, Rp228.17 billion.

According to Heru Firdausi Syarif, President Director of IRRA, the In Vitro Diagnostic product segment contributed 92% of total revenue, down from 99% in the same period last year.

Despite the decline in portion, in vitro diagnostic products still grew 10% (YoY) in the first quarter of this year.

The non-electro-medical medical device segment, Oneject Syringe products, grew 872% (YoY) and contributed 7% to total revenue.

Other income, including new products such as Avimac, BD, HMD, and others, contributed 1% to the total revenue.

In line with 2021, we were able to increase the portion of sales to non-government companies, both from corporations and retailers, in the first quarter of this year." The increase in the non-government portion has